Doctors: Cuba’s Coronavirus Miracle Cure ‘Harmful to

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone energy_wave #43535
560
Doctors: Cuba’s Coronavirus Miracle Cure
‘Harmful to the Lives of Thousands Worldwide’
< >

GettyImages-1206754199-200x150.png

The human rights NGO Cuban Prisoners Defenders published an article on Friday citing three Cuban medical researchers who concluded that the communist regime’s publicity campaign for Interferon alpha-2b, which it claims can cure Chinese coronavirus, is a “serious crime against world public health.”

“When the Government of Cuba assures that the Interferon developed in Cuba cures the coronavirus, it is committing a serious crime against world public health, since this drug not only lacks any scientific proof, but also where it has been tested has already given null results of encouragement,” the doctors concluded, urging the World Health Organization (W.H.O.) to formally condemn the Cuban Communist Party for urging off-label use of a dangerous drug when no clinical trials or scientific confirmations exist that it works.

Interferons are “involved in alerting the cellular immune system to viral infection of host cells. Interferons not only exhibit important antiviral effects but also exert a key influence on the quality of the cellular immune responses and amplify antigen presentation to specific T cells.” A study published in 2004 in the Journal of Clinical Virology found that interferon-beta can “strongly” block multiplication of the Sudden Acute Respiratory Syndrome (SARS) virus, a type of coronavirus, in human cells, but that interferon-alpha and interferon-gamma did not appear to have the same effect.

The Wuhan coronavirus is believed to be closely related to the SARS coronavirus. Cuba has spent months promoting a domestically developed interferon – interferon-alpha 2b – as a successful antiviral against the Wuhan virus, offering little to no evidence.

The doctors writing the Cuban Prisoners Defenders article warn that the use of interferon-alpha can cause severe side effects in patients while potentially having no effect on the Chinese coronavirus.

“Eminent Cuban doctors who have helped to prepare this report have witnessed its use in the elderly hospitalized with severe, community and hospital pneumonia – now classified as associated with health care – and have attested to Prisoners Defenders of the null reduction in mortality,” the report reads. “The existence of the corresponding clinical trials that justify their use is also unknown.”

The doctors note that the Cuban Communist Party’s argument in favor of the drug is simply that many who have taken it have also survived a Chinese coronavirus infection, which they conclude is insufficient evidence for global use of a drug with severe side effects.

If we consider that most patients develop mild or uncomplicated forms of the disease – some without symptoms – around approx. 14% can present severe forms with the need to receive oxygen, and another approx. 5% may require admission to Intensive Care units, how is it possible to ensure that the good evolution of most patients is due to the use of Heberferon [the brand name for Cuban interferon-alpha 2b] and not to the natural course of the disease?

If there are no minimally serious scientific protocols, with a control group, that is, patients who do not receive this drug to compare the evolution with those who do, and even other placebo control groups, the results are more than questionable and are not minimally serious.

It does not have the minimum necessary to be considered a scientific investigation.

As interferon-alpha has been used to treat hepatitis, the report quotes a hepatologist, Edward Mena, who states that their use results in a “very strong and difficult treatment.”

“The side effects are like you’re in chemical therapy. Patients have nausea, vomiting, body pain, anemia; platelets, white blood cells are lowered … it is a very strong and difficult treatment. The side effects are many,” Mena reportedly said.

The drug could “kill, rather than cure patients,” the doctors say.

Granma, the official publication of the Cuban Communist Party, proclaimed in March that the Cuban interferon was showing “effectiveness in treating patients with the new SARS Cov-2 coronavirus.” It thanked Fidel Castro – a lawyer, not a virologist, by trade – for the “visionary thinking” that created the interferon and claimed that Cuban and Chinese scientists came up with the treatment together. Granma had previously stated that Cuba was somehow developing 22 drugs to fight coronavirus, none of them accepted as treatments for the Wuhan virus.

Interferon-alpha 2b’s use against coronavirus in Wuhan, where the virus originated, has become part of the Cuban state media lore about its success. Yet the doctors writing for Cuban Prisoners Defenders say “experts [in Wuhan] come to tell us to ‘try if you want, but we have tried it and we have not obtained evidence of its benefits.'”

Cuban Prisoners Defenders concludes that the “reckless and dangerous” use and promotion of the drug is an attempt by the Cuban government to enrich itself even further off of its medical businesses, the largest of which is its $11-billion-a-year slave doctor trade.

“Cuba generates from 2 to 6 times the national income of tourism through the “rent” in a state of slavery of doctors that are sent to more than 60 countries in the world,” the doctors write.

While no drug has received universal approval as a safe treatment for coronavirus, the use of interferon-beta – not the interferon Cuba is promoting – is part of a drug cocktail undergoing trials under the W.H.O.’s auspices. Testing has reportedly begun on the use of interferon-beta along with two antivirals, Science magazine reported in March. One of the researchers the magazine quoted warned, “if it is given late in the disease it could easily lead to worse tissue damage instead of helping patients.”

Cuba has documented 923 cases of Chinese coronavirus as of Friday; 31 people have died, according to the communist government.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 2

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Amwell Revolutionizes Digital Care Platforms in 2026

Updated Category News Views 2

Amwell's Bold Move in Virtual Care Funny how in today’s digital age, where everyone is glued to their screens, healthcare can still feel like trying to piece together a jigsaw puzzle with missing pieces. But Amwell seems to have cracked the code, redefining digital care delivery like few others. Just recently, they bagged Frost & Sullivan's 2026 United States Technology...

Continue Reading
Papa John's Faces Securities Class Action Over Missteps

Updated Category News Views 1

Papa John's Stock Takes a Nosedive Here's a hot potato for you—Papa John's International, Inc. (NASDAQ: PZZA) just got slapped with a securities class action. This ain't a pie you want a slice of, not after the dough they lost in a day's trading frenzy. On August 6, our friends at Papa John's sent their investors scrambling as their stock tumbled from $29.75 to a stark...

Continue Reading
2026 AI Talent Study Reveals Growth and Gaps

Updated Category News Views 2

Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...

Continue Reading
GlocalMe Unveils Mobile Connectivity Innovations at IFA 2026

Updated Category News Views 2

Stepping into the Connectivity Future at IFA 2026 GlocalMe, a name synonymous with global mobile connections, made a splash at the IFA 2026 in Berlin. Equipped with a lineup built for the future, their presentation focused on lifestyle gadgets designed for constant online access. In a world where digital connection feels as vital as air, they've aligned perfectly with the...

Continue Reading
EF English Live's Approach to Workplace Confidence

Updated Category News Views 3

Pioneering English Confidence for the Global Workplace Stepping into a meeting with international partners requires more than just textbook knowledge of English. It's about confidently expressing ideas, adapting on the fly, and engaging with global colleagues. Enter EF English Live, a leader in transforming workplace communication through targeted English learning. Expert...

Continue Reading
Potomac Edison Eyes Rate Hike for System Overhaul

Updated Category News Views 0

FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...

Continue Reading
NOVOSENSE's Bold Performance Amid Rapid IC Demand

Updated Category News Views 1

Surge in Revenue Growth Marks a Milestone for NOVOSENSE Give a pat on the back to NOVOSENSE (HKEX: 02676), because reporting a robust 66.73% bump in first-half revenue isn't small potatoes in today's tech landscape. This translates to around $374.54 million rolling into their coffers, which is quite a spectacle if you're watching the trend of sequential revenue growth...

Continue Reading
Orbis Celebrates 20 Years of Eye Care in Macau

Updated Category News Views 2

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Continue Reading
Rho Adds Credit Card Payments to Invoices

Updated Category News Views 2

Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Culinary Excellence with illycaffè's Star Chefs

Updated Category News Views 275

A Celebration of Culinary Talent at illycaffè During an exclusive event marking the prestigious gathering of top chefs, illycaffè takes center stage as a champion of sustainable, high-quality coffee. This immersive celebration brought together numerous culinary talents as illycaffè proudly acknowledges the remarkable achievements of its Chef Ambassador program....

Continue Reading
Forecasting the Climate Adaptation Market's Significant Growth

Updated Category News Views 84

Market Outlook for Climate Adaptation The global climate adaptation market is on an impressive growth trajectory, anticipated to increase from USD 20.85 billion in recent years to an incredible USD 49.24 billion by the early 2030s, reflecting a robust compound annual growth rate (CAGR) of 10.0%. Understanding Climate Adaptation Climate adaptation refers to the necessary...

Continue Reading
HRC World PLC Transitioning to Aquis Stock Exchange for Share Trading

Updated Category News Views 228

HRC World PLC Moves Trading to Aquis Stock Exchange HRC WORLD PLC TICKER: HRC ISIN: GB00BZ3CDY20 HRC World Plc has exciting news for its shareholders regarding a major shift in its trading venue. The company will be transitioning its ordinary shares of €0.01 each from Nasdaq Copenhagen to the Aquis Stock Exchange (AQSE) in the UK. This change reflects HRC's commitment...

Continue Reading
Roundhill Investments Achieves New Milestone with $8 Billion AUM

Updated Category News Views 172

Roundhill Investments Surpasses $8 Billion in AUM Roundhill Investments has achieved an impressive milestone by surpassing $8 billion in assets under management (AUM). This achievement highlights the firm's rapid growth trajectory and commitment to delivering innovative financial products for investors. Remarkable Growth in 2025 Over the course of this year, Roundhill has...

Continue Reading
Leidos Secures Contract to Enhance Organ Transplant Network

Updated Category News Views 30

Leidos Secures Contract for Organ Transplant Network Modernization Leidos announced a significant move aimed at transforming the organ transplantation landscape by securing a crucial contract. This partnership with the U.S. Department of Health and Human Services will modernize the Organ Procurement and Transplant Network (OPTN), a system essential for streamlining vital...

Continue Reading